<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="56672"><DrugName>setrobuvir</DrugName><DrugNamesKey><Name id="42953559">setrobuvir</Name></DrugNamesKey><DrugSynonyms><Name><Value>AN-025-1</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>non-nucleoside polymerase inhibitor (hepatitis C virus infection), Anadys</Value></Name><Name><Value>non-nucleoside polymerase inhibitor (HCV infection), Anadys</Value></Name><Name><Value>ANA-59X</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>setrobuvir</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>ANA-598</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RG-7790</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RO-5466731</Value></Name><Name><Value>1071517-39-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="27894">Anadys Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="19446">Roche Holding AG</Company><Company id="27894">Anadys Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="56672" type="Drug"><TargetEntity id="455400" type="siDrug"></TargetEntity><TargetEntity id="685150" type="siDrug">Setrobuvir</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="27894" type="Company"><TargetEntity id="4295916149" type="organizationId">Anadys Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"/><TargetEntity id="D019698" type="MeSH"/><TargetEntity id="-776640207" type="omicsDisease"/><TargetEntity id="430" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity></SourceEntity><SourceEntity id="12358" type="Action"><TargetEntity id="1529" type="Mechanism">RNA-Directed RNA Polymerase (NS5B) (Viral) Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="153">Hepatitis C virus infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="12358">Hepatitis C virus NS5B polymerase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2018-04-19T06:01:42.000Z</LastModificationDate><ChangeDateLast>2018-04-20T00:00:00.000Z</ChangeDateLast><AddedDate>2007-01-19T15:14:58.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt;, following its acquisition of &lt;ulink linkID="27894" linkType="Company"&gt;Anadys Pharmaceuticals&lt;/ulink&gt;, was developing setrobuvir (ANA-598; RG-7790; RO-5466731), a formulation of the lead in the AN-025-1 series  of non-nucleoside NS5B polymerase inhibitors (which includes the ANA-59X  subseries), for the potential oral treatment of hepatitis C virus (HCV) infection [&lt;ulink linkID="758816" linkType="Reference"&gt;758816&lt;/ulink&gt;], [&lt;ulink linkID="1196907" linkType="Reference"&gt;1196907&lt;/ulink&gt;], [&lt;ulink linkID="1259334" linkType="Reference"&gt;1259334&lt;/ulink&gt;], [&lt;ulink linkID="1259887" linkType="Reference"&gt;1259887&lt;/ulink&gt;], [&lt;ulink linkID="1307071" linkType="Reference"&gt;1307071&lt;/ulink&gt;], [&lt;ulink linkID="1316417" linkType="Reference"&gt;1316417&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2009, dosing  began in  a phase II combination trial [&lt;ulink linkID="1040429" linkType="Reference"&gt;1040429&lt;/ulink&gt;]. In January 2014, the company was planning to file a marketing application in 2016 [&lt;ulink linkID="1519748" linkType="Reference"&gt;1519748&lt;/ulink&gt;]. However, by April 2015,  development of the drug had been discontinued  [&lt;ulink linkID="1653537" linkType="Reference"&gt;1653537&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In December 2008, the FDA awarded setrobuvir Fast Track status for chronic HCV infection [&lt;ulink linkID="967808" linkType="Reference"&gt;967808&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, the company was planning to file a marketing application in 2016 [&lt;ulink linkID="1519748" linkType="Reference"&gt;1519748&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2012, a randomized, open-label, phase II trial (&lt;ulink linkID="88706" linkType="Protocol"&gt;NCT01628094&lt;/ulink&gt;; NP28266; 2012-000638-21; ANNAPURNA) began to study the safety and efficacy of a combination of setrobuvir, &lt;ulink linkID="51283" linkType="Drug"&gt;danoprevir&lt;/ulink&gt;, &lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt;, and ribavirin (&lt;ulink linkID="71886" linkType="Drug"&gt;Copegus&lt;/ulink&gt;), with or without &lt;ulink linkID="55333" linkType="Drug"&gt;mericitabine&lt;/ulink&gt;, in chronic HCV genotype 1 patients (estimated n = 180) in the US, Australia, New Zealand, Poland, France, and Germany, who are treatment-naive or null responders to interferon [&lt;ulink linkID="1307071" linkType="Reference"&gt;1307071&lt;/ulink&gt;], [&lt;ulink linkID="1316417" linkType="Reference"&gt;1316417&lt;/ulink&gt;].  In November 2013, interim data were presented at The Liver Meeting 2013 in Washington DC. Patients (n = 110) received  mericitabine + ribavirin (1000 or 1200 mg) followed by 12 (arm 1) or 24 (arm 2) weeks with setrobuvir (800 mg bid and 400 mg thereafter) + danoprevir (100/100 mg bid) + ribavirin + mericitabine (1000 mg bid) or 24 (arm 3) weeks of treatment with setrobuvir + danoprevir + ribavirin. In arm 4 and 5, patients received mericitabine + ribavirin  and  setrobuvir + danoprevir + ribavirin with and without mericitabine. The proportions of patients who had rapid virological response, sustained virological response at week 4 (SVR) and SVR12 (primary endpoint) were 100, 43 and 43%, respectively, in arm 1; 96, 74 and 70%, respectively, in arm 2; 100, 96 and 96%, respectively, in arm 4 and 100, 77and 68%, respectively, in arm 5. Treatments were well tolerated [&lt;ulink linkID="1495790" linkType="Reference"&gt;1495790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2011, a randomized, double-blind, placebo-controlled, phase II trial (&lt;ulink linkID="146897" linkType="Protocol"&gt;NCT01903954&lt;/ulink&gt;; NP28302) began in the US to assess the efficacy and safety of setrobuvir in combination with standard of care in treatment-naive or -experienced patients (n = 283) with chronic genotype 1 HCV infection. Treatment-naive patients received either setrobuvir (always dosed at 800 mg oral bid loading dose on day 1 followed by 200 mg oral bid dose thereafter) or placebo combined with &lt;ulink linkID="23625" linkType="Drug"&gt;Pegasys&lt;/ulink&gt; (peginterferon alfa-2a) and &lt;ulink linkID="23625" linkType="Drug"&gt;Copegus&lt;/ulink&gt; (ribavirin) for 28 or 48 weeks depending on response. Treatment-experienced patients were all dosed for 48 weeks. Those categorized as relapsers, partial responders and viral breakthrough to previous pegylated interferon and ribavirin therapy received either setrobuvir or placebo combined with Pegasys and Copegus, and those  categorized as null-responders received setrobuvir plus Pegasys and Copegus. The primary endpoint was the sustained virological response at 24 weeks after discontinuation of the study drugs (SVR24). In May 2013, the trial had completed [&lt;ulink linkID="1525988" linkType="Reference"&gt;1525988&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, a 48-week, phase IIb trial (&lt;ulink linkID="146897" linkType="Protocol"&gt;NCT01281423&lt;/ulink&gt;; ANA598-505, Control No. 143490) of setrobuvir in combination with &lt;ulink linkID="23625" linkType="Drug"&gt;Pegasys&lt;/ulink&gt; and &lt;ulink linkID="5369" linkType="Drug"&gt;Copegus&lt;/ulink&gt; (ribavirin) began in treatment-naive and -experienced patients with chronic disease (n = 266) in the US, Canada, Australia and New Zealand [&lt;ulink linkID="1146279" linkType="Reference"&gt;1146279&lt;/ulink&gt;], [&lt;ulink linkID="1281242" linkType="Reference"&gt;1281242&lt;/ulink&gt;]. In January 2011, patient screening and dosing had begun [&lt;ulink linkID="1158790" linkType="Reference"&gt;1158790&lt;/ulink&gt;], [&lt;ulink linkID="1163816" linkType="Reference"&gt;1163816&lt;/ulink&gt;]; by August 2011, enrollment was complete [&lt;ulink linkID="1213518" linkType="Reference"&gt;1213518&lt;/ulink&gt;]. In October 2011, interim data were reported.     Antiviral response was demonstrated in patients who had failed prior treatment. Data showed a favorable safety profile and the drug was well tolerated. Of 238 patients, 78% of treatment-naive patients and 76% of -experienced patients achieved undetectable levels of virus at week 12 (cEVR), compared with 56 and 44 % of patients receiving placebo plus Pegasys/ribavirin. At week 8, 71% of treatment-naive patients showed undetectable levels of virus, meeting the response-guided criteria for shortening treatment to 28 weeks. Prior null-responding patients (29 %) achieved the cEVR with setrobuvir plus Pegasys/ribavirin and 36 % of these patients showed undetectable levels of virus at week 18, while no prior null-responder patients were treated in placebo arm. At 12 weeks, the viral breakthrough rates in treatment-naive and -experienced patients were 2.9 and 3.6%, respectively [&lt;ulink linkID="1230205" linkType="Reference"&gt;1230205&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2009, a phase II trial (&lt;ulink linkID="60404" linkType="Protocol"&gt;NCT00978497&lt;/ulink&gt;; ANA598-504) began to assess  setrobuvir (200 or 400 mg bid) plus &lt;ulink linkID="23625" linkType="Drug"&gt;Pegasys&lt;/ulink&gt; and &lt;ulink linkID="5369" linkType="Drug"&gt;ribavirin&lt;/ulink&gt;   or placebo plus interferon-alpha and ribavirin for 12 weeks  in treatment-naive genotype 1 HCV patients (n = 90)  in the US. Patients would receive a 800-mg loading dose of the drug on day 1. The primary endpoints were the percentage of patients with undetectable virus at 4 and 12 weeks (early virological response).  Secondary  endpoints included safety, tolerability and rapid and sustained virological responses  [&lt;ulink linkID="1015578" linkType="Reference"&gt;1015578&lt;/ulink&gt;], [&lt;ulink linkID="1040429" linkType="Reference"&gt;1040429&lt;/ulink&gt;], [&lt;ulink linkID="1525957" linkType="Reference"&gt;1525957&lt;/ulink&gt;]. In October 2009, enrollment of the first cohort in the trial had completed [&lt;ulink linkID="1053054" linkType="Reference"&gt;1053054&lt;/ulink&gt;]. In December 2009, 4-week results from the 200-mg bid dose cohort  showed that 56% of those receiving the drug had undetectable levels of virus compared with 20% of placebo patients; at  that time, enrollment in the 400-mg bid dose cohort had been initiated [&lt;ulink linkID="1064688" linkType="Reference"&gt;1064688&lt;/ulink&gt;]. In January 2010, dosing in the 200-mg bid cohort was completed and dosing of all patients in the 400-mg bid cohort had started [&lt;ulink linkID="1070278" linkType="Reference"&gt;1070278&lt;/ulink&gt;]. In February 2010, 12-week data from the 200-mg bid dose cohort were reported. A total of 73% of treated patients achieved undetectable levels of virus compared with 71% of placebo-treated patients, and no viral rebound was experienced. At that time, patients achieving undetectable viral levels at weeks 4 and 12 were to be randomized to stop treatment at weeks 24 or 48 and would be followed for a further 24 weeks to determine the rate of sustained virological response.  Complete early virological response  was seen in 74 and 71% of  patients with genotypes 1a and 1b, respectively [&lt;ulink linkID="1077291" linkType="Reference"&gt;1077291&lt;/ulink&gt;], [&lt;ulink linkID="1077289" linkType="Reference"&gt;1077289&lt;/ulink&gt;]. In April 2010, further data were presented at the 45th Annual Meeting of the EASL in Vienna, Austria.  At 8 weeks, 400 mg bid of setrobuvir produced undetectable virus levels in 72% of patients. No patients experienced viral breakthrough at this dose [&lt;ulink linkID="1090809" linkType="Reference"&gt;1090809&lt;/ulink&gt;]. Also by that time, 12 weeks of dosing in the 400 mg bid and control groups was complete [&lt;ulink linkID="1094303" linkType="Reference"&gt;1094303&lt;/ulink&gt;]. In May 2010, completed 12-week  data from the 400-mg bid dose cohort were reported. Complete early virological response was seen in  75% of patients.  At that time, additional  24-week  data  from    the 200-mg bid dose cohort   showed that 17 of 18 patients who had undetectable levels of virus at week 12 remained undetectable at 24 weeks, and an additional two patients who had low detectable levels of virus at week 12 achieved undetectable levels of virus at week 24 [&lt;ulink linkID="1102332" linkType="Reference"&gt;1102332&lt;/ulink&gt;]. In July 2010, further data showed 6 of 6 patients in the 200 mg cohort, who were randomized to stop treatment at 24 weeks, maintained undetectable levels of virus for the following 12 weeks. Patients in the 200-mg cohort who continued treatment from week 24 also maintained undetectable levels of virus at week 36 [&lt;ulink linkID="1119713" linkType="Reference"&gt;1119713&lt;/ulink&gt;]. In October 2010, similar data were presented at the 61st AASLD conference in Boston, MA. In IL28B studies it was shown that patients with either  the C/C and C/T alleles had an increase in viral response. The safety data did not differ significantly from the control arm, except that in  the 400-mg group a higher percentage of patients experienced a rash [&lt;ulink linkID="1145935" linkType="Reference"&gt;1145935&lt;/ulink&gt;]. Further data presented at the meeting on this trial demonstrated that regardless of the IL28B genotype, setrobuvir decreased viral load during the first week of treatment [&lt;ulink linkID="1148314" linkType="Reference"&gt;1148314&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In October 2008, a US, 3-day, placebo-controlled  study (&lt;ulink linkID="33229" linkType="Protocol"&gt;NCT00782353&lt;/ulink&gt;; ANA598-502) began to assess  tolerability, pharmacokinetics and viral kinetics following twice-daily dosing with 200, 400 or 800 mg of setrobuvir in 30 naive genotype 1 HCV patients for 3 days [&lt;ulink linkID="945818" linkType="Reference"&gt;945818&lt;/ulink&gt;], [&lt;ulink linkID="956875" linkType="Reference"&gt;956875&lt;/ulink&gt;]. In January 2009, setrobuvir-treated patients  from the first cohort showed a median viral load decrease of 2.5 log10. Three genotype 1a and five genotype 1b setrobuvir-treated patients showed a median viral load decline of 1.6 log10 and 2.6 log10, respectively. No drug-treated patients showed viral rebound and setrobuvir was well-tolerated with no serious adverse events reported. At that time, enrollment in the 400 mg cohort was ongoing [&lt;ulink linkID="974874" linkType="Reference"&gt;974874&lt;/ulink&gt;]. Further data were reported in April 2009 at the EASL meeting in Copenhagen, Denmark. At the end of treatment,  the median HCV reduction at all dose levels was over 2 log10 (99%). At the 200-mg bid dose, the median viral load reduction was 2.4 log10; at 400 mg bid, the median viral load fell by 2.3 log10; and at      800 mg bid, a 2.9 log10 reduction was observed. In genotype 1a patientsmedian reductions were 1.4 log10, 1.8 log10, and 2.5 log10      at 200, 400  and 800 mg bid, respectively. In 10 of the 12 genotype 1a      patients who received setrobuvir, viral load was still falling at the      end of the 3 days of treatment.  In genotype 1b patients median reductions of 2.6 log10, 2.5 log10 and 3.2 log10 were seen at 200, 400      and 800 mg bid, respectively. No viral      rebound was associated with setrobuvir and the drug was well tolerated [&lt;ulink linkID="1002803" linkType="Reference"&gt;1002803&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By February 2009, Anadys had begun a 14-day, safety and pharmacokinetic study in healthy volunteers. Subjects would receive 400, 800 or 1200 of the drug qd or 600 mg bid.  [&lt;ulink linkID="987348" linkType="Reference"&gt;987348&lt;/ulink&gt;]. By April 2009, enrollment had been completed, with 30 subjects enrolled. The drug was well tolerated and had a plasma half-life of approximately 24 h with  steady-state levels reached after 6 to 7 days of dosing. These data  confirmed previously reported data [&lt;ulink linkID="1002803" linkType="Reference"&gt;1002803&lt;/ulink&gt;], [&lt;ulink linkID="1077291" linkType="Reference"&gt;1077291&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, the company planned to file an IND for setrobuvir in 2Q08 [&lt;ulink linkID="806351" linkType="Reference"&gt;806351&lt;/ulink&gt;]. In June 2008, a US phase I study began to assess the safety, tolerability and pharmacokinetics of single-ascending-doses of setrobuvir in 40 healthy volunteers [&lt;ulink linkID="912437" linkType="Reference"&gt;912437&lt;/ulink&gt;]. In September 2008, the company reported positive results. In the study, subjects received setrobuvir at single doses starting at 400 mg. At the 2000 mg dose level, it was administered in fed or fasted conditions. Setrobuvir was well tolerated at all doses with no serious adverse events reported. Pharmacokinetic results showed that all doses achieved sustained plasma levels of setrobuvir with a half-life of more than 24 h, supporting once- or twice-daily dosing, and are predicted to display substantial antiviral activity based on preclinical results. In October 2008, further data  reported  showed that the drug was tolerated at doses up to 3000 mg and that its half-life was 24 to 30 h [&lt;ulink linkID="956875" linkType="Reference"&gt;956875&lt;/ulink&gt;]. In November 2008, similar data were reported at the 59th annual meeting of the American Association for the Study of Liver Diseases in San Francisco, CA [&lt;ulink linkID="958261" linkType="Reference"&gt;958261&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2010,  preclinical results were reported that demonstrated that activity was enhanced and resistance was suppressed when setrobuvir was combined with other anti-HCV agents in vitro  [&lt;ulink linkID="1086247" linkType="Reference"&gt;1086247&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2008, preclinical data showing setrobuvir to be synergistic with interferon-alpha, &lt;ulink linkID="10096" linkType="Drug"&gt;telaprevir&lt;/ulink&gt; and &lt;ulink linkID="51269" linkType="Drug"&gt;PSI-6130&lt;/ulink&gt; were presented at the 59th annual meeting of the American Association for the Study of Liver Diseases in San Francisco, CA [&lt;ulink linkID="958261" linkType="Reference"&gt;958261&lt;/ulink&gt;]. Similar data were reported in April 2009 at the EASL meeting in Copenhagen, Denmark. These data also showed that setrobuvir was active against mutants resistant to other antivirals [&lt;ulink linkID="1002803" linkType="Reference"&gt;1002803&lt;/ulink&gt;]. In April 2010, similar data were presented for setrobuvir at the 23rd International Conference on Antiviral Research in San Francisco, CA [&lt;ulink linkID="1092514" linkType="Reference"&gt;1092514&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 2Q08, preclinical evaluation of setrobuvir was completed and the drug was shown to be well tolerated at all doses assessed in 28-day GLP toxicology studies [&lt;ulink linkID="956875" linkType="Reference"&gt;956875&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2008, the company began long-term chronic toxicology studies of setrobuvir in rats (6 months) and monkeys (9 months) . The company expected to have 3-month data from the studies in 2Q09 [&lt;ulink linkID="945818" linkType="Reference"&gt;945818&lt;/ulink&gt;], [&lt;ulink linkID="987348" linkType="Reference"&gt;987348&lt;/ulink&gt;]. In April 2009, 13-week data were reported. The no adverse effect observed level (NAEOL) was 1000 mg/kg in monkeys and male rats; in female rates NAEOL was 300 mg/kg. By that time, dosing in the rat study was complete and dosing in the monkey study was scheduled to complete in June 2009 [&lt;ulink linkID="1002803" linkType="Reference"&gt;1002803&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2008, preliminary  data from a primate HCV model were reported. Two animals infected with HCV genotype 1b received once-daily oral 30 mg/kg doses of setrobuvir for four days. At 48 h, viral load was reduced by 2.2 and 2.6 log10 in both animals. In one animal, viral load reduction was sustained throughout the remaining dosing period, while the second animal had a modest rise in viral load over days 3 and 4 [&lt;ulink linkID="864623" linkType="Reference"&gt;864623&lt;/ulink&gt;]. In chimpanzees, the bioavailability of the drug was between 50 to 70% [&lt;ulink linkID="869410" linkType="Reference"&gt;869410&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2007, setrobuvir had been selected as a clinical candidate, and the company planned to file an IND in 2Q08. By that time, setrobuvir had shown activity against HCV genotype 1 NS5b polymerase and in HCV replicon assays. The compound also had good in vitro metabolic stability and did not inhibit human CYP enzymes. In vivo, the drug had high oral bioavailability and good tolerability [&lt;ulink linkID="806351" linkType="Reference"&gt;806351&lt;/ulink&gt;]. In September 2007, further data were presented at the 14th International Symposium on Hepatitis C Virus and Related Viruses.  Setrobuvir was well tolerated in toxicology studies at doses from 1 to 1000 mg/kg.  In in vivo preclinical studies trough plasma concentrations  24 hours post dosing exceeded the EC95 for HCV genotype 1a and 1b replicon inhibition [&lt;ulink linkID="829526" linkType="Reference"&gt;829526&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007,  data describing the optimization of the series were presented at the 20th International Conference on Antiviral Research in Palm Springs, CA. The optimized NS5B polymerase inhibitors had nanomolar potency in biochemical and replicon assays, as well as with promising metabolic properties, Sustained drug levels were observed in  plasma and the liver [&lt;ulink linkID="790250" linkType="Reference"&gt;790250&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Roche owns worldwide rights, through its acquisition of originator Anadys in November 2011[&lt;ulink linkID="1259887" linkType="Reference"&gt;1259887&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2015-04-22T00:00:00.000Z</StatusDate><Source id="1653537" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2015-04-22T00:00:00.000Z</StatusDate><Source id="1653537" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2015-04-22T00:00:00.000Z</StatusDate><Source id="1653537" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2015-04-22T00:00:00.000Z</StatusDate><Source id="1653537" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2015-04-22T00:00:00.000Z</StatusDate><Source id="1653537" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="27894">Anadys Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2009-09-09T00:00:00.000Z</StatusDate><Source id="1040429" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27894">Anadys Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2010-12-31T00:00:00.000Z</StatusDate><Source id="1281242" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27894">Anadys Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2010-12-31T00:00:00.000Z</StatusDate><Source id="1281242" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27894">Anadys Pharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2010-12-31T00:00:00.000Z</StatusDate><Source id="1281242" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2011-11-23T00:00:00.000Z</StatusDate><Source id="1259887" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2011-11-23T00:00:00.000Z</StatusDate><Source id="1259887" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2011-11-23T00:00:00.000Z</StatusDate><Source id="1259887" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2012-06-22T00:00:00.000Z</StatusDate><Source id="1307071" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2011-11-23T00:00:00.000Z</StatusDate><Source id="1259887" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27894">Anadys Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2007-01-11T00:00:00.000Z</StatusDate><Source id="758816" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27894">Anadys Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2008-06-02T00:00:00.000Z</StatusDate><Source id="912437" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="27894">Anadys Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="153">Hepatitis C virus infection</Indication><AwardedIndication>Treatment of chronic Hepatitis C Virus (HCV) infection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2008-12-01T00:00:00.000Z</MileStoneDate><Source id="967808" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-03112"><Name>Hepatitis C virus NS5B polymerase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CS(=O)(=O)Nc1ccc2c(c1)S(=O)(=O)N=C(N2)C3=C([C@@H]4[C@H]5CC[C@H](C5)[C@@H]4N(C3=O)Cc6ccc(cc6)F)O</Smiles></StructureSmiles><Deals><Deal id="132748" title="Anadys to receive grant under QTDP program in US"/></Deals><PatentFamilies><PatentFamily id="1777581" number="WO-2012016995" title="Prediction of HCV viral kinetics in interferon-free treatment"/><PatentFamily id="2428491" number="WO-2012170536" title="[1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid"/><PatentFamily id="2655673" number="WO-2013188396" title="Combination of therapeutic agents for treating HCV infection"/><PatentFamily id="2771059" number="WO-2014108806" title="A novel process for the preparation of N-(4-nitro-2-sulfamoly-phenyl)-malonamic acid methyl ester and N-(4-amino-2-sulfamoyl-phenyl)-malonamic acid methyl ester"/><PatentFamily id="2857765" number="WO-2015001068" title="Primers and methods for detecting human hepatitis C virus (HCV) variants in an isolated sample"/><PatentFamily id="3649255" number="CN-106668055" title="A triple compound preparation for treating hepatitis"/><PatentFamily id="729148" number="WO-2007150001" title="Pyrro[1,2-b]pyridazinone compounds"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hospital Vall D'Hebron" id="1003065"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centre for Biomedical Network Research on Rare Diseases (CIBERER)" id="1054179"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centro De Investigación Biomédica En Red De Enfermedades Hepáticas Y Digestivas (Ciberehd)" id="1063304"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Provincial Hospital" id="1067506"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centro de Investigación Biomédica en Red" id="1097770"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>